Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | KITE-439 |
Synonyms | |
Therapy Description |
KITE-439 consists of autologous T-cells engineered to express a T-cell receptor that recognizes HLA-A*02:01-restricted human papillomavirus type 16 isoform E7 (HPV16 E7) protein, potentially resulting in antitumor activity of cells expressing HPV16 E7 (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
KITE-439 | KITE 439 | KITE-439 consists of autologous T-cells engineered to express a T-cell receptor that recognizes HLA-A*02:01-restricted human papillomavirus type 16 isoform E7 (HPV16 E7) protein, potentially resulting in antitumor activity of cells expressing HPV16 E7 (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03912831 | Phase I | Cyclophosphamide + Fludarabine KITE-439 | Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers | Terminated | USA | 0 |
NCT05041309 | Phase II | KITE-585 KITE-222 Brexucabtagene autoleucel KITE-718 axicabtagene ciloleucel KITE-439 | Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells | Enrolling by invitation | USA | NLD | ISR | GBR | FRA | DEU | CAN | AUS | 1 |